MLR 1023
Chemical Name: 5-(3-Methylphenoxy)-2(1H)-pyrimidinone
Purity: ≥99%
Biological Activity
MLR 1023 is a selective allosteric activator of Lyn kinase (EC50 = 63 nM); displays no significant activity against a range of 47 other kinases, including other Src family kinases such as Fyn, Lck and Src kinase. Reduces blood glucose levels without affecting in vivo insulin secretion. Orally bioavailable.Technical Data
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Background References
-
MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivo.
Saporito et al.
J.Pharmacol.Exp.Ther., 2012;342:15 -
The Lyn kinase activator MLR-1023 is a novel Ins receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes.
Ochman et al.
J.Pharmacol.Exp.Ther., 2012;342:23
Product Datasheets
Citations for MLR 1023
The citations listed below are publications that use Tocris products. Selected citations for MLR 1023 include:
2 Citations: Showing 1 - 2
-
Cdk5 and GSK3β inhibit fast endophilin-mediated endocytosis.
Authors: Konstantinos Et al.
Nat Commun 2021;12:2424
-
Src inhibition attenuates polyglutamine-mediated neuromuscular degeneration in spinal and bulbar muscular atrophy.
Authors: Iida Et al.
Nat Commun 2019;10:4262
FAQs
No product specific FAQs exist for this product, however you may
View all Small Molecule FAQsReviews for MLR 1023
There are currently no reviews for this product. Be the first to review MLR 1023 and earn rewards!
Have you used MLR 1023?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
